Third Rock Ventures LLC, a venture capital firm with offices in Boston, announced the formation of Ember Therapeutics with a $34 million Series A financing. In a press release, Ember said it looks to leverage findings in brown-fat biology and recent breakthroughs in selective insulin sensitivity to develop treatments for metabolic diseases, including Type 2 diabetes and obesity. Ember’s interim chief executive is Louis Tartaglia, a partner at Third Rock Ventures.